
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt about

If you have sold or transferred

Shenzhen Heparlink Pharmaceutical Group Co., Ltd.,

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



()

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

2022 WORK REPORT OF THE BOARD OF DIRECTORS
2022 WORK REPORT OF THE SUPERVISORY COMMITTEE
2022 ANNUAL REPORT AND ITS SUMMARY,
H SHARES RESULTS ANNOUNCEMENT,
H SHARES 2022 ANNUAL REPORT, 2022 CORPORATE GOVERNANCE REPORT AND
2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
2022 FINAL FINANCIAL REPORT
2022 PROFIT DISTRIBUTION PROPOSAL
RE-APPOINTMENT OF AUDITORS OF THE COMPANY
ELECTION OF THE SIXTH SESSION OF THE BOARD
REMUNERATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF
THE SIXTH SESSION OF THE BOARD
ELECTION OF THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE
PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND CASH FLOW MANAGEMENT
USING INTERNAL FUNDS
APPLICATION FOR CREDIT LINE AND PROVIDING GUARANTEE TO CERTAIN BANKS FOR 2023
AMENDMENT OF ARTICLES OF ASSOCIATION
AND
NOTICE OF THE 2022 ANNUAL GENERAL MEETING

AGM), 2023
 H Shares
 H Shares
 H Shares
 H Shares
 H Shares
 H Shares

CONTENTS

	<i>Page</i>
DEFINITIONS	1
LETTER FROM THE BOARD	3
1.	4
2.	4
2022W	4
2022W	5
2022 A, H2, 2022 A, H2, 2022 H2, 2022 A, H2, 2022	5
2022	5
2022	5
2022	5
2022	6
2022	6
2022	7
2022	7
2022	9
2023	9
2023	9
3. A, H2, H2, H2	9
4.	10
5.	11
APPENDIX I – PROFILES OF THE PROPOSED SIXTH SESSION OF THE BOARD ...	12
APPENDIX II – AMENDMENT OF ARTICLES OF ASSOCIATION	18
NOTICE OF THE 2022 ANNUAL GENERAL MEETING	20

Note: ...

DEFINITIONS

In this circular, unless the context otherwise requires, the following terms shall have the following meanings:

7 A 

LETTER FROM THE BOARD



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

Executive Directors:

★ · · · · · (Chairman of the Board)
★ · · · · · (Deputy General Manager)
★ · 2' · · · (General Manager)

Independent non-executive Directors:

★ · · · · ·
★ W · · · · · Z · · · · ·

Registered office in the PRC:

· · · · · 21 · · · · ·
2' · · · · ·
§ · · · · ·

*Principal place of business
in Hong Kong:*

4724, 471-
2' H · · · · ·
30 H · · · · ·
W · · · · · H · · · · ·

A · · · 20, 2023

To the Shareholders

2' · · · · · ★ · · · · ·

**2022 WORK REPORT OF THE BOARD OF DIRECTORS
2022 WORK REPORT OF THE SUPERVISORY COMMITTEE
2022 ANNUAL REPORT AND ITS SUMMARY,
H SHARES RESULTS ANNOUNCEMENT,
H SHARES 2022 ANNUAL REPORT,
2022 CORPORATE GOVERNANCE REPORT AND
2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
2022 FINAL FINANCIAL REPORT
2022 PROFIT DISTRIBUTION PROPOSAL
RE-APPOINTMENT OF AUDITORS OF THE COMPANY
ELECTION OF THE SIXTH SESSION OF THE BOARD
REMUNERATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF
THE SIXTH SESSION OF THE BOARD
ELECTION OF THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE
PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND
CASH FLOW MANAGEMENT
USING INTERNAL FUNDS
APPLICATION FOR CREDIT LINE AND PROVIDING GUARANTEE TO
CERTAIN BANKS FOR 2023
AMENDMENT OF ARTICLES OF ASSOCIATION**

LETTER FROM THE BOARD

1. INTRODUCTION

... (...)
A ...

- A ... A ... :
- (1) ... 2022W ...
 - (2) ... 2022W ... 2 § ...
 - (3) ... 2022 A ... 2 § ... H 2 ... A ... H 2 ... 2022 ... 2022 ... 2 § ...
 - (4) ... 2022 ...
 - (5) ... 2022 ...
 - (6) ...
 - (7) ...
 - (8) ...
 - (9) ... 2 § ...
- A ... A ... :

2. MATTERS TO BE CONSIDERED AT THE ANNUAL GENERAL MEETING

i. 2022 Work Report of the Board of Directors

... 2022 A ... H ... 2 § ...
... 2022W ... 2 § ...
... 29, 2023 ... A ...

LETTER FROM THE BOARD

ii. 2022 Work Report of the Supervisory Committee

The Supervisory Committee has reviewed the 2022 Work Report of the Supervisory Committee, which was approved by the Board of Directors on December 29, 2023.

iii. 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report

The Board of Directors has reviewed the 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report, which were approved by the Board of Directors on December 29, 2023.

iv. 2022 Final Financial Report

The Board of Directors has reviewed the 2022 Final Financial Report, which was approved by the Board of Directors on December 29, 2023.

v. 2022 Profit Distribution Proposal

The Board of Directors has reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Directors on December 29, 2023.

The Board of Directors has reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Directors on December 29, 2023.

LETTER FROM THE BOARD

vi. Re-appointment of auditors of the Company

At a meeting of the Board of Directors of the Company held on 29, 2023, the Board resolved to re-appoint the current auditors of the Company, H & H, to audit the financial statements of the Company for the year ending 2023. The Board also resolved to re-appoint the current auditors of the Company, A, to audit the financial statements of the Company for the year ending 2023.

vii. Election of the sixth session of the Board

At a meeting of the Board of Directors of the Company held on 29, 2023, the Board resolved to elect the sixth session of the Board of Directors of the Company. The Board also resolved to elect the following members to the Board of Directors of the Company: (Mr. Li), (Mr. Shan), (Dr. Lu), (Mr. Zhang), (Mr. Huang), (Mr. Yi), ()12.7, ()12.8 ()12.A

LETTER FROM THE BOARD

§ 2

3.4 A 14

H

H

A

A

A

viii. Remuneration of independent non-executive Directors of the sixth session of the Board

100,000

§ 2

§ 2

A

ix. Election of the sixth session of the Supervisory Committee

184

§ 2

§ 2

(Ms. Tang)

Z

(Mr. Zheng)

H

§ 2

§ 2

§ 2

A

LETTER FROM THE BOARD

... Z, ...
... Z, Z (鄭澤輝), ... 53, ...
... 2006. ... W ...
... 1992 ...
... 2011.

... H (唐海均), ... 44, ...
... 2001 ...
... 2007. ...
... 2014.

... Z, ...
... A ...
... A ...
... A ...
... Z ...

... H ...

... Z, ...
... H ...

... 13.51(2)(c) ... 13.51(2)() ...
... Z, ...

... Z, ...

LETTER FROM THE BOARD

... 29, 2023. A ...

x. Purchase of Wealth Management Products and Cash Flow Management Using Internal Funds

... 29, 2023. A ...

... 29, 2023. A ...

xi. Application for Credit Line and Providing Guarantee to Certain Banks for 2023

... 2023. A ...

... 29, 2023. A ...

xii. Amendment of Articles of Association

... 29, 2023. A ...

... A ...

3. ANNUAL GENERAL MEETING AND CLOSURE OF REGISTER OF MEMBERS OF H SHARES

... 2024. A ...

LETTER FROM THE BOARD

17, 2023

16, 2023

22, 2023

17, 2023

22, 2023

17, 2023

16, 2023

22, 2023

29, 2023

31, 2023

17, 2023

25, 2023

31, 2023

2022

4. VOTING BY POLL

13.39(4)

A

A

A

20

LETTER FROM THE BOARD

5. RECOMMENDATION

§ 2, A

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Li Li
Chairman

A

Non-independent Directors

(i) *Mr. Li Li*

(李鋌), 59, H § 2
28 H § 2
A § 2
2012
1, 21 () / 808 001 -022136 8110 0 0 10 70.

(ii) Ms. Li Tan

(李坦), 58, ... 28 ... A ... 1998. ... 2007; ... (H ...) ... 2014; ... 2010; ... H ... 2013; ... A ... 2015; ... 2016. ... 1987 ... 2005. ... 922,391,179 A ... 73.96% ... A ... 408,041,280 A ... 99.00% ... 474,029,899 A ... 99.00% ... 40,320,000 A ...

Dr. Lu Chuan (呂川), 53, is a Chinese national and currently resides in Shanghai, China. He has been a professor and vice president of Shanghai University of Applied Science and Technology since 2014. He served as the president of Shanghai University of Applied Science and Technology from 2005 to 2014. He is also a member of the Shanghai Municipal People's Government and the Shanghai Municipal Government. He has been a member of the Shanghai Municipal People's Government since 2014. He has been a member of the Shanghai Municipal Government since 2014. He has been a member of the Shanghai Municipal People's Government since 2014. He has been a member of the Shanghai Municipal Government since 2014. He has been a member of the Shanghai Municipal People's Government since 2014. He has been a member of the Shanghai Municipal Government since 2014.

Dr. Lu Chuan (呂川), 53, is a Chinese national and currently resides in Shanghai, China. He has been a professor and vice president of Shanghai University of Applied Science and Technology since 2014. He served as the president of Shanghai University of Applied Science and Technology from 2005 to 2014. He is also a member of the Shanghai Municipal People's Government and the Shanghai Municipal Government. He has been a member of the Shanghai Municipal People's Government since 2014. He has been a member of the Shanghai Municipal Government since 2014. He has been a member of the Shanghai Municipal People's Government since 2014. He has been a member of the Shanghai Municipal Government since 2014.

Independent Non-Executive Directors

(v) Dr. Lu Chuan

Dr. Lu Chuan (呂川), 53, is a Chinese national and currently resides in Shanghai, China. He has been a professor and vice president of Shanghai University of Applied Science and Technology since 2014. He served as the president of Shanghai University of Applied Science and Technology from 2005 to 2014. He is also a member of the Shanghai Municipal People's Government and the Shanghai Municipal Government. He has been a member of the Shanghai Municipal People's Government since 2014. He has been a member of the Shanghai Municipal Government since 2014. He has been a member of the Shanghai Municipal People's Government since 2014. He has been a member of the Shanghai Municipal Government since 2014.

Dr. Lu Chuan (呂川), 53, is a Chinese national and currently resides in Shanghai, China. He has been a professor and vice president of Shanghai University of Applied Science and Technology since 2014. He served as the president of Shanghai University of Applied Science and Technology from 2005 to 2014. He is also a member of the Shanghai Municipal People's Government and the Shanghai Municipal Government. He has been a member of the Shanghai Municipal People's Government since 2014. He has been a member of the Shanghai Municipal Government since 2014. He has been a member of the Shanghai Municipal People's Government since 2014. He has been a member of the Shanghai Municipal Government since 2014.

A ... §

(vi) Mr. Huang Peng

Mr. H (黃鵬), 74, 1949, H 2003. H 1995 1985. H 2 2 1988, (新時代企業家研究院) H : 601890), W (: 301180), J (: 300819) & : 603828). H 2

H A H A H A H A

A ... H §

(vii) Mr. Yi Ming

Mr. Yi (易銘), 46, 1977, H 2002 A H 2014. H (H) A 2003 H 2012. H Z (A) A 2013 J 2018. H A A 2018


H A H A H A H A

A ... §

Article 14. The Board of Directors shall have the authority to borrow money on behalf of the Association and to execute any promissory notes, mortgages, deeds, or other instruments necessary to carry out its duties. The Board of Directors shall also have the authority to execute any promissory notes, mortgages, deeds, or other instruments necessary to carry out its duties.

Existing Provisions of the Articles of Association	Proposed Amendments to the Articles of Association
<p>Article 14. The Board of Directors shall have the authority to borrow money on behalf of the Association and to execute any promissory notes, mortgages, deeds, or other instruments necessary to carry out its duties. The Board of Directors shall also have the authority to execute any promissory notes, mortgages, deeds, or other instruments necessary to carry out its duties.</p>	<p>Article 14. The Board of Directors shall have the authority to borrow money on behalf of the Association and to execute any promissory notes, mortgages, deeds, or other instruments necessary to carry out its duties. The Board of Directors shall also have the authority to execute any promissory notes, mortgages, deeds, or other instruments necessary to carry out its duties.</p>
<p>Article 97 A § 2. The Board of Directors shall have the authority to borrow money on behalf of the Association and to execute any promissory notes, mortgages, deeds, or other instruments necessary to carry out its duties. The Board of Directors shall also have the authority to execute any promissory notes, mortgages, deeds, or other instruments necessary to carry out its duties.</p> <p>A § 2. The Board of Directors shall have the authority to borrow money on behalf of the Association and to execute any promissory notes, mortgages, deeds, or other instruments necessary to carry out its duties. The Board of Directors shall also have the authority to execute any promissory notes, mortgages, deeds, or other instruments necessary to carry out its duties.</p>	<p>Article 97 A § 2. The Board of Directors shall have the authority to borrow money on behalf of the Association and to execute any promissory notes, mortgages, deeds, or other instruments necessary to carry out its duties. The Board of Directors shall also have the authority to execute any promissory notes, mortgages, deeds, or other instruments necessary to carry out its duties.</p> <p>A § 2. The Board of Directors shall have the authority to borrow money on behalf of the Association and to execute any promissory notes, mortgages, deeds, or other instruments necessary to carry out its duties. The Board of Directors shall also have the authority to execute any promissory notes, mortgages, deeds, or other instruments necessary to carry out its duties.</p>

Existing Provisions of the Articles of Association	Proposed Amendments to the Articles of Association
A 2 § W 2 § A 2 § 2 § 2 §	A 2 § W 2 § A 2 § 2 § 2 §
Article 150	Article 150
Article 156	Article 156
Article 158	Article 158



NOTICE OF THE 2022 ANNUAL GENERAL MEETING

ORDINARY RESOLUTION

8. That the accounts of the Company for the financial year ended 31st December 2021, as shown in the financial statements, be approved and the directors be discharged from their liability in respect of those accounts;

SPECIAL RESOLUTION

9. That the accounts of the Company for the financial year ended 31st December 2021, as shown in the financial statements, be approved and the directors be discharged from their liability in respect of those accounts;

ORDINARY RESOLUTIONS

10. That the accounts of the Company for the financial year ended 31st December 2021, as shown in the financial statements, be approved and the directors be discharged from their liability in respect of those accounts;

11. That the accounts of the Company for the financial year ended 31st December 2021, as shown in the financial statements, be approved and the directors be discharged from their liability in respect of those accounts;

11.01 That the accounts of the Company for the financial year ended 31st December 2021, as shown in the financial statements, be approved and the directors be discharged from their liability in respect of those accounts;

11.02 That the accounts of the Company for the financial year ended 31st December 2021, as shown in the financial statements, be approved and the directors be discharged from their liability in respect of those accounts;

11.03 That the accounts of the Company for the financial year ended 31st December 2021, as shown in the financial statements, be approved and the directors be discharged from their liability in respect of those accounts;

11.04 That the accounts of the Company for the financial year ended 31st December 2021, as shown in the financial statements, be approved and the directors be discharged from their liability in respect of those accounts;

NOTICE OF THE 2022 ANNUAL GENERAL MEETING

12. 2022年12月31日止年度业绩摘要及全年业绩报告全文(包括摘要)；
- 12.01 2022年12月31日止年度业绩摘要全文；
- 12.02 2022年12月31日止年度业绩报告全文(包括摘要)；
- 12.03 2022年12月31日止年度业绩报告全文(包括摘要)；
13. 2022年12月31日止年度业绩摘要及全年业绩报告全文(包括摘要)；
- 13.01 2022年12月31日止年度业绩摘要全文；
- 13.02 2022年12月31日止年度业绩报告全文(包括摘要)；

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

2023年12月20日

NOTICE OF THE 2022 ANNUAL GENERAL MEETING

(iii) $\frac{2}{3}$ of the votes cast by the holders of the shares entitled to vote at the meeting, or if a poll is taken, $\frac{2}{3}$ of the votes cast by the holders of the shares which carry the majority of the voting rights at the meeting, shall be sufficient to pass ordinary resolutions, and $\frac{3}{4}$ of the votes cast by the holders of the shares entitled to vote at the meeting, or if a poll is taken, $\frac{3}{4}$ of the votes cast by the holders of the shares which carry the majority of the voting rights at the meeting, shall be sufficient to pass special resolutions.

9. The Board of Directors may, if it thinks fit, call a meeting of the shareholders to elect members of the Board of Directors.